Diabetic Neuropathic Pain Market Growth Outlook 2036: Epidemiology, Pipeline Therapies, and Revenue Forecast - DelveInsight

DelveInsight's "Diabetic Neuropathic Pain Market Insights, Epidemiology, and Market Forecast-2036′′ report offers an in-depth understanding of the Diabetic Neuropathic Pain, historical and forecasted epidemiology as well as the Diabetic Neuropathic Pain market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Diabetic Neuropathic Pain market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Diabetic Neuropathic Pain Market Forecast
https://www.delveinsight.com/sample-request/diabetic-neuropathic-pain-dnp-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Diabetic Neuropathic Pain Market Report:
• The Diabetic Neuropathic Pain market size is anticipated to grow with a significant CAGR during the study period (2022-2036).
• In March 2026, Eli Lilly and Company, Vertex Pharmaceuticals, and Lexicon Pharmaceuticals were identified among key companies actively developing innovative therapies for Diabetic Peripheral Neuropathy. The update emphasized growing industry focus on sodium channel modulators, neuroprotective agents, and disease-modifying approaches to improve long-term neuropathic pain management.
• In January 2026, Lexicon Pharmaceuticals was highlighted among the leading companies advancing diabetic neuropathy therapies through its investigational AAK1 inhibitor LX9211 (Pilavapadin). The update noted continued advancement of the diabetic neuropathy pipeline, with LX9211 remaining one of the notable mid-stage therapies targeting neuropathic pain through a non-opioid mechanism.
• According to Ziegler et al., 13-26% of diabetic individuals experience neuropathic pain. According The neuropathic pain is present in 13-26% of diabetic patients. From a survey in Augsburg, Germany, the prevalence of painful polyneuropathy was found to be 13.3% in diabetic subjects.
• As per the insights, a significantly greater proportion of females (38%) than males (31%) reported painful neuropathy symptoms. DNP is more common in females as compared to males due to hormonal variances, smaller nerve fibers, and genetic influences, potentially elevating its prevalence.
• The risk of painful neuropathy symptoms in type 2 diabetic patients was 83% higher than in type 1 patients; this risk doubled after adjusting for differences in age and diabetes duration.
• The prevalence of DNP ranges from 10% to 20% of patients with diabetes and from 40% to 50% of those with diabetic neuropathies.
• The prevalence of painful symptoms (NSS ≥5) and DNP (NSS ≥5 and NDS ≥3) was 34 and 21%, respectively in the UK. Painful symptoms occurred in 26% of patients without neuropathy (NDS ≤2) and 60% of patients with severe neuropathy (NDS >8).
• Key Diabetic Neuropathic Pain Companies: Vertex Pharmaceuticals, Lexicon Pharmaceuticals/Bristol-Myers Squibb, Centrexion Therapeutics, Rigshospitalet, CSPC Ouyi Pharmaceutical, Reata, Lexicon Pharmaceuticals, Jemincare, Eli Lilly and Company, GlaxoSmithKline, Apurano Pharmaceuticals, and others.
• Key Diabetic Neuropathic Pain Therapies: Suzetrigine (VX-548), Pilavapadin (LX9211), CNTX6016, Incobotulinumtoxin-A 100 UNIT Injection, pregabalin sustained-release tablets, RTA 901, LX9211, JMKX000623, LY3556050, GSK3858279, Adezunap (AP707), and others
• The Diabetic Neuropathic Pain epidemiology based on gender analyzed that Diabetic Neuropathic Pain affects females more as compared to males
• The Diabetic Neuropathic Pain market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Diabetic Neuropathic Pain pipeline products will significantly revolutionize the Diabetic Neuropathic Pain market dynamics.

Diabetic Neuropathic Pain Overview
The most frequent cause of neuropathic pain and a well-known consequence of diabetes is diabetic neuropathy. DNP affects about one-third of all diabetes patients. After ruling out other potential causes, it is characterised as the existence of signs and/or symptoms of nerve dysfunction in diabetic individuals. While sustained high blood sugar (glucose) levels can harm the nerves throughout your body, DNP is most severe in the legs and feet.

Get a Free sample for the Diabetic Neuropathic Pain Market Report
https://www.delveinsight.com/report-store/diabetic-neuropathic-pain-dnp-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Diabetic Neuropathic Pain Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2022 to 2036. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Diabetic Neuropathic Pain Epidemiology Segmentation:
The Diabetic Neuropathic Pain market report proffers epidemiological analysis for the study period 2022-2036 in the 7MM segmented into:
• Total Prevalence of Diabetic Neuropathic Pain
• Prevalent Cases of Diabetic Neuropathic Pain by severity
• Gender-specific Prevalence of Diabetic Neuropathic Pain
• Diagnosed Cases of Episodic and Chronic Diabetic Neuropathic Pain

Download the report to understand which factors are driving Diabetic Neuropathic Pain epidemiology trends @ Diabetic Neuropathic Pain Epidemiology Forecast
https://www.delveinsight.com/sample-request/diabetic-neuropathic-pain-dnp-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Diabetic Neuropathic Pain Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Diabetic Neuropathic Pain market or expected to get launched during the study period. The analysis covers Diabetic Neuropathic Pain market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Diabetic Neuropathic Pain Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Diabetic Neuropathic Pain Therapies and Key Companies
• Suzetrigine (VX-548): Vertex Pharmaceuticals
• Pilavapadin (LX9211): Lexicon Pharmaceuticals/Bristol-Myers Squibb
• CNTX6016: Centrexion Therapeutics
• Incobotulinumtoxin-A 100 UNIT Injection: Rigshospitalet, Denmark
• pregabalin sustained-release tablets: CSPC Ouyi Pharmaceutical Co., Ltd.
• RTA 901: Reata
• LX9211: Lexicon Pharmaceuticals
• JMKX000623: Jemincare
• LY3556050: Eli Lilly and Company
• GSK3858279: GlaxoSmithKline
• Adezunap (AP707): Apurano Pharmaceuticals

Discover more about therapies set to grab major Diabetic Neuropathic Pain market share @ Diabetic Neuropathic Pain Treatment Market
https://www.delveinsight.com/sample-request/diabetic-neuropathic-pain-dnp-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Diabetic Neuropathic Pain Market Drivers
• Rising diabetes burden: The growing prevalence of Type 1 and Type 2 diabetes is expanding the population at risk of diabetic peripheral neuropathy and associated neuropathic pain.
• High unmet treatment need: Diabetic neuropathic pain remains difficult to manage, with many patients experiencing inadequate pain relief and reduced quality of life, creating demand for more effective therapies.
• Growing demand for novel therapies: The limitations of existing treatments are encouraging development of therapies with improved efficacy, safety, tolerability, and novel mechanisms of action.
• Increasing disease awareness and diagnosis: Greater recognition of diabetic neuropathy and its symptoms is supporting earlier diagnosis and treatment, while awareness gaps remain an important opportunity for market expansion.
• Advances in clinical research: Increasing focus on disease-modifying approaches, improved clinical trial designs, and more meaningful outcome measures is supporting innovation in the diabetic neuropathic pain pipeline.

Diabetic Neuropathic Pain Market Barriers
• Limited efficacy of current therapies: Existing analgesics often provide only partial pain relief, while achieving complete pain resolution is uncommon, highlighting a significant therapeutic gap.
• Safety and tolerability concerns: Common treatments may cause adverse effects such as dizziness, drowsiness, nausea, fatigue, or cognitive effects, which can affect adherence and long-term treatment use.
• Lack of disease-modifying treatments: Most available therapies focus on managing pain symptoms rather than reversing or slowing the underlying nerve damage.
• Underdiagnosis and treatment gaps: Despite its prevalence and substantial impact, diabetic neuropathic pain remains underdiagnosed and undertreated, limiting timely access to appropriate therapies.
• Clinical development challenges: Disease heterogeneity, difficulties in patient recruitment, and the lack of standardized or clinically meaningful endpoints can increase the complexity and risk of developing new therapies.

Scope of the Diabetic Neuropathic Pain Market Report
• Study Period: 2022-2036
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Diabetic Neuropathic Pain Companies: Vertex Pharmaceuticals, Lexicon Pharmaceuticals/Bristol-Myers Squibb, Centrexion Therapeutics, CSPC Ouyi Pharmaceutical, Reata, Lexicon Pharmaceuticals, Jemincare, Eli Lilly and Company, GlaxoSmithKline, Apurano Pharmaceuticals, and others
• Key Diabetic Neuropathic Pain Therapies: Suzetrigine (VX-548), Pilavapadin (LX9211), CNTX6016, Incobotulinumtoxin-A 100 UNIT Injection, pregabalin sustained-release tablets, RTA 901, LX9211, JMKX000623, LY3556050, GSK3858279, Adezunap (AP707), and others
• Diabetic Neuropathic Pain Therapeutic Assessment: Diabetic Neuropathic Pain current marketed and Diabetic Neuropathic Pain emerging therapies
• Diabetic Neuropathic Pain Market Dynamics: Diabetic Neuropathic Pain market drivers and Diabetic Neuropathic Pain market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Diabetic Neuropathic Pain Unmet Needs, KOL's views, Analyst's views, Diabetic Neuropathic Pain Market Access and Reimbursement

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.